Lynnet Koh

Lynnet has successfully led the research, development, manufacturing of Targazyme’s immuno- oncology drugs from idea stage to completion of phase 2 clinical trials where Targazyme’s drug is shown to improve cancer patient survival and quality of life as well as positioning the company for Phase 3 readiness/multiple shots on goal. Key milestones and awards received: FDA Phase 3 Special Protocol Assessment, multiple FDA Orphan Drug DesignaOons, worldwide patents. Major validation received: $40MM+ of prestigious peer-reviewed medical awards for the advancement of the fucosyltransferase recombinant human enzyme technology with leading clinical collaborators, publications in Blood, Clinical Cancer Research and Nature, collaborations with Astellas, Kyowa Hakko Kirin, Vidacord, Poseida TherapeuOcs, Allogene and leading research centers such as MD Anderson Cancer Center and OMRF.

Lynnet has a passion for, and a proven track record with leading transformative technology innovations from the idea stage through design, development, manufacturing, global launch, and achievement of market-leading commercial revenues across multiple industries. They include Targazyme’s novel enzymes with their potential for improving the efficacy, safety, and cost of care for cell therapy, the world’s first generation caller ID product (AT&T Bell Labs) which enables people to see the caller’s name and number, first-generation wireless systems (AT&T Bell Labs) which enables people to be reached anyone, anyplace, anywhere; first-generation voice/video/data infrastructure products (Cisco Systems) which enables people to have voice/ video communications over the internet. Several of the products that she managed commanded #1 market share in their sectors and won best in class awards. Companies, where she held key general management/program leadership roles, include Cisco Systems, AT&T, Qualcomm.